Amgen will present updated data from its bispecific T cell engager (BiTE®) portfolio in two oral presentations. Data include the first safety and efficacy findings from the ongoing Phase 1 dose escalation study of AMG 701, an investigational half-life extended BiTE immuno-oncology therapy targeting B-cell maturation antigen (BCMA), in patients with heavily pre-treated relapsed/refractory multiple myeloma. Analyses from the BLINCYTO® (blinatumomab) Phase 3 ‘215 study in children with high-risk first relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) will also be presented.
“Amgen is advancing one of the most robust bispecific pipelines in the industry,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “In 2020 alone, we are presenting first-in-human data for four assets from the BiTE platform, including these data at ASH with our BCMA-targeted half-life extended BiTE therapy AMG 701.”
Updated progression-free survival and additional MRD-negativity analyses from the KYPROLIS® (carfilzomib) Phase 3 CANDOR study will also be presented.
Abstracts are available at https://www.hematology.org/meetings/annual-meeting/abstracts. Learn more about Amgen’s development of innovative medicines for novel targets in difficult-to-treat tumors at AmgenOncology.com/medical.
To register, click here.